



## Press Release |

### **IBA OPENS A NEW RADIOPHARMACEUTICALS PRODUCTION CENTER IN DINNINGTON, UK**

Embargo until 5:40 pm (Belgian time) – July 3, 2007

**Louvain-la-Neuve, Belgium, July 3, 2007** – IBA (Ion Beam Applications S.A.: Reuters IOBA.t.BR and Bloomberg IBAB.BB) announced today that it has received approval from the UK authorities to manufacture out of its new PET (Positron Emission Tomography) radiopharmaceuticals production unit in Dinnington (South Yorkshire), United Kingdom.

This new facility is the latest addition to the IBA distribution network, which includes 35 PET radiopharmaceuticals production centers across the world. The facility will serve the North of England. Dinnington is one component of the IBA distribution network in UK which also includes the Guildford (Surrey) facility built to serve the South of England and scheduled to open during the autumn 2007.

After Brussels (Belgium) and Udine (Italy), Dinnington is the third PET radiopharmaceuticals production facility opened by IBA in Europe this year, bringing the number of operational European centers to 17.

“The opening of this new center, reinforces the position of IBA as the largest radiopharmaceuticals distribution network in Europe and the world”, said Pierre Mottet, Chief Executive Officer of IBA. “We are excited to be part of the accelerated development of PET that is taking place in UK right now. Providing reliably PET radiopharmaceuticals and also novel radioisotopes is the commitment of IBA across the world. Our ambition is not only to provide a superior PET service to our customers but also to partner with them in the development of tracers of tomorrow”, added Mr. Mottet.



## Press Release |

### **ABOUT IBA**

IBA delivers solutions of exceptional precision in the fields of **cancer diagnosis and therapy**. The company also provides sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT, is integrated into the NextEconomy market segment, and belongs to the BelMid index.

Website: <http://www.iba-worldwide.com>.

IBA is organized into two sectors of business:

- The Production and Distribution of Radioisotopes which covers radiopharmaceutical tracers used in medical imaging, the main one being FDG (F-18 Fluorodeoxyglucose);
- The Technology & Equipment sector which forms the technological basis for a number of the company's activities and covers the development, manufacturing, marketing and services linked to the equipment, including particle accelerators, for imaging, therapy, dosimetry or sterilization and ionization.

### Contact

#### **IBA**

Paul-Emmanuel Goethals  
Director, Corporate Business Development  
& Investor Relations

Phone: +32 10 47 58 16

[paul-emmanuel.goethals@iba-group.com](mailto:paul-emmanuel.goethals@iba-group.com)